Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Conformatie Europeene (CE) marking for Interventional Technologies (IVT) cutting balloon:

This article was originally published in Clinica

Executive Summary

Interventional Technologies has been awarded CE marking for its cutting balloon catheter, which combines conventional balloon angioplasty (PTCA) with microsurgical blades. Already cleared for the Japanese and Canadian markets, the cutting balloon this year successfully completed global multi-centre, non-randomised studies in over 300 patients, says San Diego-based IVT. Still in progress are a single-centre non-randomised trial in Toyohashi, Japan (400-plus patients), and a Phase III global trial that will randomise 1,244 patients against conventional PTCA. The latter study, which is being carried out in the US, Canada, Belgium, the Netherlands and France, will examine restenosis and target vessel revascularisation rates at six-month follow-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT093583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel